165 related articles for article (PubMed ID: 17853308)
21. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
[TBL] [Abstract][Full Text] [Related]
22. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
[TBL] [Abstract][Full Text] [Related]
23. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
[TBL] [Abstract][Full Text] [Related]
24. Efalizumab: an overview.
Leonardi CL
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S98-104. PubMed ID: 12894132
[TBL] [Abstract][Full Text] [Related]
25. Efalizumab-associated papular psoriasis.
Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
[TBL] [Abstract][Full Text] [Related]
26. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
[TBL] [Abstract][Full Text] [Related]
27. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
[TBL] [Abstract][Full Text] [Related]
28. Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH; Langley RG; Ho V
J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
[TBL] [Abstract][Full Text] [Related]
29. Efalizumab for the treatment of moderate to severe plaque psoriasis.
Jordan JK
Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
[TBL] [Abstract][Full Text] [Related]
30. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo.
Fernandez-Obregon AC
J Drugs Dermatol; 2008 Jul; 7(7):679-81. PubMed ID: 18664161
[TBL] [Abstract][Full Text] [Related]
31. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
[TBL] [Abstract][Full Text] [Related]
32. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
33. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
34. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
35. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
Gottlieb AB; Hamilton T; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S154-63. PubMed ID: 16488337
[TBL] [Abstract][Full Text] [Related]
36. Efalizumab-induced autoimmune pancytopenia.
Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
38. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
39. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
[TBL] [Abstract][Full Text] [Related]
40. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
